Systemic immune activation and biomarkers of nonceliac wheat/gluten sensitivity
AssigneeThe Trustees of Columbia University in the City of New York
InventorArmin Alaedini
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe Trustees of Columbia University in the City of New York
InventorArmin Alaedini
Estimating the term…
The present invention provides a method of using increased levels of one or more biomarkers to identify subjects having non-celiac gluten sensitivity or non-celiac wheat sensitivity. The identification would aid the physician or health professional to determine a specific treatment for the patient, for example, a diet that eliminates wheat, rye, and/or barley. In one embodiment, the biomarkers are one or more of soluble CD 14 (sCD14), lipopolysaccharide-binding protein (LBP), anti-lipopolysaccharide antibodies, anti-flagellin antibodies, anti-gliadin antibodies, and intestinal fatty acid-binding protein (FABP2). The present invention also provides a method of using the same markers to monitor the response to treatment for non-celiac wheat sensitivity in a subject.
1-8. (canceled)
A method of treating a subject having non-celiac wheat sensitivity, comprising the steps of:
A method of monitoring response to a treatment for non-celiac wheat sensitivity in a subject, comprising the step of determining blood levels of one or more markers in said subject before and after said treatment, said markers are selected from the group consisting of soluble CD 14 (sCD14), lipopolysaccharide-binding protein (LBP), anti-lipopolysaccharide antibodies, anti-flagellin antibodies, anti-gliadin antibodies, and intestinal fatty acid-binding protein (FABP2), wherein decreased levels of said markers in said subject after said treatment indicate that said subject has responded to said treatment, otherwise the subject has not responded to the treatment.
A method of determining a course of treatment for non-celiac wheat sensitivity in a subject, comprising the step of determining blood levels of one or more markers in said subject before and after said treatment, said markers are selected from the group consisting of soluble CD 14 (sCD14), lipopolysaccharide-binding protein (LBP), anti-lipopolysaccharide antibodies, anti-flagellin antibodies, anti-gliadin antibodies, and intestinal fatty acid-binding protein (FABP2),
A kit that aids in diagnosis of non-celiac wheat sensitivity in a subject, comprising reagents that detect the presence of one or more markers in a sample from said subject, said markers are selected from the group consisting of soluble CD 14 (sCD14), lipopolysaccharide-binding protein (LBP), anti-lipopolysaccharide antibodies, anti-flagellin antibodies, anti-gliadin antibodies, and intestinal fatty acid-binding protein (FABP2).
(canceled)
Dependencies are inferred from the claim text.